David Brooks, Non-Executive Director

RNS Number : 0585V

Impact Healthcare REIT PLC

18 July 2018

 

18 July 2018

Impact Healthcare REIT plc

(the "Company" and with its subsidiaries, the "Group")

David Brooks, Non-Executive Director

The Board of Directors of Impact Healthcare REIT plc (ticker: IHR) announces with great sadness that David Brooks, Non-Executive Director, died suddenly on 13 July 2018.

Commenting on the sad news, Rupert Barclay, Chairman of Impact Healthcare REIT plc, said: 

"Our sincere and deepest sympathies are very much with David's family and his wife, Wendy. It was a great privilege to know David personally, he will be greatly missed for his wise counsel and significant contributions to the Board."

FOR FURTHER INFORMATION, PLEASE CONTACT:

Impact Health Partners LLP Mahesh Patel Andrew Cowley	via Newgate Communications
Winterflood Securities Limited Joe Winkley Neil Langford	Tel: [phone]
Newgate Communications (PR Adviser) James Benjamin Anna Geffert Patrick Hanrahan	Tel: [phone] Email: [e-mail]

The Company's LEI is 213800AX3FHPMJL4IJ53.

Further information on Impact Healthcare REIT is available at www.impactreit.uk

NOTES:

The Group is a real estate investment trust ("REIT") which aims to provide shareholders with an attractive return, principally in the form of quarterly income distributions and with the potential for capital and income growth, through exposure to a diversified portfolio of healthcare real estate opportunities, in particular residential care homes. The Group's investment policy is to acquire, renovate, extend and redevelop high quality healthcare real estate assets in the UK and lease those assets primarily to healthcare operators providing residential healthcare services under full repairing and insuring leases.

The Group will have paid an aggregate dividend of 6.0 pence per share for the first 12 months from Admission, which equates to a yield of 6 per cent. per annum on the IPO Issue Price, payable in quarterly instalments.

The Group's Ordinary Shares were admitted to trading on the main market of the London Stock Exchange, Specialist Fund Segment, on 7 March 2017.

 

END

 

 

BOASFIFDAFASESW